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Abstract
Background: Prostate cancer (PCa) is the most common non-skin cancer in USA and the second leading cause of
cancer death in Western Countries. Despite the high mortality associated with PCa, the only established risk factors
are age, race and family history. A possible association between metabolic syndrome (MetS) and PCa was firstly
described in 2004 and several subsequent studies in biopsy cohorts have shown conflicting results. Aim of our
multicentre prospective study was to investigate the association between MetS and PCa in men undergoing radical
prostatectomy (RP).
Methods: From January 2012 to June 2015, 349 consecutive men undergoing RP for PCa at three centres in Italy
were enrolled into a prospective database. Body Mass Index (BMI) as well as waist circumference was measured
before RP. Blood samples were also collected and tested for total PSA, fasting glucose, triglycerides and HDLs.
Blood pressure was also recorded. We evaluated the association between MetS, defined according to Adult
Treatment Panel III, PCa stage (advanced stage defined as pT ≥ 3 or N1) and grade (high grade defined as Gleason
Score ≥ 4 + 3) using logistic regression analyses.
Results: Median age and preoperative PSA levels were 66 years (IQR: 61-69) and 7 ng/ml (IQR: 5-10), respectively.
Median BMI was 26.12 kg/m2 (IQR 24-29) with 56 (16 %) obese (BMI ≥ 30 kg/m2) patients and 87 (25 %) patients
with MetS. At pathological evaluation, advanced PCa and high-grade disease were present in 126 (36 %) and 145
(41.5 %) patients, respectively. MetS was significantly associated with advanced PCa (45/87, 51 % vs 81/262, 31 %;
p = 0.008) and high-grade disease (47/87, 54 % vs 98/262, 37 %; p = 0.001). On multivariable analysis, MetS was an
independent predictor of pathological stage ≥ pT3a or N1 (OR: 2.227; CI: 1.273-3.893; p = 0.005) and Gleason score ≥
4 + 3 (OR: 2.007, CI: 1.175-3.428; p = 0.011).
Conclusions: We firstly demonstrated in a European radical retropubic prostatectomy cohort study that MetS is
associated with an increased risk of high-grade and advanced prostate cancer. Further studies with long term
follow-up should evaluate the impact of Mets on PCa survival.
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Background
Prostate cancer (PCa) represents the most common
non-skin cancer in Western Countries and the second
leading cause of cancer death. Notwithstanding the high
mortality rate associated with PCa, the only established
risk factors are age, race, and family history [1]. Large
geographic disparity in PCa risk suggests that lifestyle
factors may contribute to the aetiology of the disease. In
fact, Asian men have incidence rates 10- to 15- fold
lower than those observed in Western Countries,
however PCa incidence in Eastern Countries and in
emigrants has increased rapidly in the last years, sug-
gesting that Westernization may represent an important
etiologic factor [2].
Metabolic syndrome (MetS) was firstly described by
Reaven in 1988 as complex disorder (Syndrome X),
namely a constellation of metabolic abnormalities that
increases the risk of coronary artery disease, cardiovas-
cular atherosclerotic diseases and diabetes mellitus type
2 (DMT2) [3]. MetS has become a major public health
problem in many Western Countries since its prevalence
has been increasing; 35-41 % of adults in the USA are
diagnosed with MetS [4]. According to the most widely
accepted definition, proposed by the National Cholesterol
Education Program’s Adult Treatment Panel III (ATPIII),
patients with at least 3 of the following factors are
considered to have MetS: abdominal obesity (waist
circumference >102 cm in men or >88 cm in
women), hypertriglyceridemia (>150 mg/dl), low high
density lipoprotein (HDL) cholesterol (<40 mg/dl in
men and <50 mg/dl in women), high blood pressure
(>130/85 mm Hg) and a high fasting blood glucose
level (>110 mg/dl) [1, 5].
Recently, increasing evidence supports the hypothesis
that different metabolic factors and MetS may be in-
volved in the development and progression of certain
types of malignancies [6–8]. A possible association
between MetS and PCa was firstly described in 2004 by
Laukkanen et al [9] and several subsequent studies in
biopsy cohorts have shown conflicting results [1, 10–18].
Aim of our multicentre prospective study was to
evaluate the association between MetS, defined accord-
ing to the ATPIII criteria, and PCa among a consecutive
series of men undergoing radical prostatectomy (RP).
Methods
From January 2012 to June 2015 a consecutive series of
men undergoing RP for PCa at three centres in Italy
were enrolled into a prospective database. The study was
approved by the Ethics committee of the coordinator
centre (Ospedale Sant’Andrea, La Sapienza University of
Rome) and then of the Regina Elena National Cancer
Institute, Rome, and San Giovanni Bosco Hospital,
Turin. All patients signed a dedicated informed consent.
Age and anthropometric parameters including waist
circumference and body mass index (BMI) were assessed
according to standardized methods and recorded from
all patients. Waist circumference was measured, using a
standard measurement strip with the patients standing
and breathing normally, at the midway between the low-
est rib margin and iliac crest [19]. BMI was calculated as
weight in kilograms divided by height in meters, squared
(kg/m2). Obesity was defined as BMI ≥30 kg/m2.
Additionally, resting blood pressure was recorded as the
first and fifth Korotkof sounds by auscultation methods
[20]. Moreover, fasting (8 hours) blood samples were
drawn from all patients during the preoperative assess-
ment evaluation and analysed for blood glucose, HDL
cholesterol, triglycerides, total Prostate Specific Antigen
(PSA) [1]. Data were used to define a binary variable for
the presence or absence of MetS, according to ATPIII
[5]. Finally, prostate volume was evaluated before
surgery by means of trans-rectal ultrasound.
As per European Association of Urology (EAU) Guide-
lines [21], surgical treatment was recommended to pa-
tients with a life expectancy of at least 10 years and a
bioptic diagnosis of PCa, clinically localized or advanced
(cT1-T3). Indication to surgery, independently from the
presence of MetS, was proposed by a local muldisciplin-
ary uro-oncology team evaluating all the prostate cancer
cases diagnosed or referred to each hospital. One
dedicated uro-pathologist in each centre performed the
histological examinations of the RP specimens.
Pathologic report was standardized [22] according to
the histological/architectural thresholds proposed by the
World Health Organization (WHO) classification of
tumor of the urinary system and male genital organs [23].
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS v.21, IBM Corp.,
Armonk, NY, USA). Evaluation of data distribution using
the Kolmogorov–Smirnov test showed a non-normal
distribution of the study data set. Differences between
groups of patients in medians for quantitative variables
and differences in distributions for categorical variables
were tested with the Kruskal Wallis one-way analysis of
variance and chi-square test, respectively. Using multiple
logistic regression with the enter method, the statistical
significant variables assessed in the univariate analysis
were entered and investigated as predictors of advanced
PCa (pathological Tumor stage ≥ pT3a and/or N1)
versus localized PCA, and in a separate model predictors
of high grade (Gleason score ≥ 4 + 3) versus low grade
were compared. The logistic regression analysis was
carried out using data from patients for whom complete
data were available. In order to reduce the risk of
redundant variables and subsequent multicollinearity,
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the variables included in the definition of the MetS were
excluded from the multivariate analysis. An alpha value
of 5 % was considered as threshold for significance. Data
are presented as median (Inter quartile range (IQR)) and
mean ± standard deviation (SD). Odds ratios (OR) and
95 % Confidence Intervals (CI) were calculated for the
parameters in each model.
Results
A total of 349 consecutive patients were enrolled (204 at
Sant’Andrea Hospital, 78 at Regina Elena Institute and
67 at San Giovanni Bosco Hospital), with a median age
and PSA of 66 (IQR: 61-69) years and 7 (IQR: 5-10) ng/ml
respectively. Median BMI was 26.12 (IQR: 24-29) with 56
subjects (16 %) being obese. Baseline patients’ characteris-
tics are summarized in Table 1. No significant differences
(p > 0.05) for clinical and pathological characteristics were
observed among the three centres (data not shown).
Metabolic Syndrome was diagnosed in 87 patients
(25 %) according to ATPIII criteria. Patients with MetS
showed higher BMI, waist circumference, fasting
glycaemia, trygliceridemia and lower HDL. No statisti-
cally significant differences were observed between the
MetS-group and the non-MetS-group regarding age
(64.92 ± 4.87 years vs 64.05 ± 6.53 years; p = 0.473),
serum PSA levels (10.80 ± 16.75 ng/ml vs 10.41 ±
12.28 ng/ml; p = 0.687) and prostate volume (53.4 ±
24.01 ml vs 55.43 ± 34 ml; p = 0.661). According to the
National Comprehensive Cancer Network (NCCN) [24]
and the preoperative available data (PSA, bioptic
Gleason Score and clinical Stage), patients with PCa
were classified into three categories: Low, Intermediate
and High risk. Overall 134 patients (38.6 %) were
diagnosed with a low risk cancer, 117 (33.7 %) with an
Intermediate risk and 96 (27.7 %) with a High risk. Meta-
bolic syndrome was significantly more prevalent (p < 0.001)
in the Intermediate (30/117; 25.6 %) and High Risk (36/96;
37.5 %) population when compared with Low risk (21/134;
15.7 %).
Overall 126 patients (36 %) were found to have a non-
organ confined prostate cancer (pT ≥ 3a) on pathological
RP report (Table 2). Nineteen (5.4 %) patients presented
positive lymph nodes (N1) and all of them had a ≥ pT3
PCa. No significant differences were observed between
subjects with advanced and localized prostate cancers in
terms of waist circumference (100.34 ± 9.22 cm vs 99.3
± 8.13 cm; p = 0.503), BMI (27.07 ± 3.79 kg/m2 vs 26.64
± 3.59 kg/m2; p = 0.149), glycaemia (103.87 ± 21.1 mg/dl
vs 100.83 ± 19.68 mg/dl; p = 0.159) and HDL (50.78 ±
12.34 mg/dl vs 52.78 ± 12.34 mg/dl; p = 0.925). Patients
with advanced prostate cancer were older (65.97 ±
5.97 years vs 63.44 ± 6.28 years; p = < 0.001) with a
higher PSA (14.54 ± 17.84 ng/ml vs 7.81 ± 4.55 ng/ml,
p < 0.001) and smaller glands (51.53 ± 29.86 ml vs 76 ±
44.05 ml, p < 0.001).
High grade PCa (Gleason Score ≥4 + 3) was diagnosed
in 145 patients (41.5 %). Patients with high grade PCa were
older (64.69 ± 6.28 years vs 63.43 ± 6.16 years; p < 0.001),
with a higher PSA (13.22 ± 18.22 ng/ml vs 8.79 ±
8.16 ng/ml; p < 0.001) and smaller glands (53.23 ±
29.54 ml vs 56.31 ± 31.57 ml; p < 0.001) (Table 2).
MetS was significantly associated with advanced PCa
(45/87, 51 % vs 81/262, 31 %; p = 0.008), pathologic nodal
involvement (9/87, 10 % vs 10/262, 4 %; p = 0.028) and
high grade PCa (47/87, 54 % vs 98/262, 37 %; p = 0.001).
On multivariable analysis serum PSA levels and MetS
were independent predictors of pathologic tumor stage ≥
3a and Gleason score ≥ 4 + 3 (Table 3).
Discussion
In our series older patients with higher PSA levels and
lower prostate volumes presented an increased risk of
advanced and high grade PCa. These data were similar
to previous experiences from our centre and from other
studies demonstrating a negative correlation between
Table 1 Patient’s characteristics according to the presence or absence of Metabolic Syndrome
Overall No MetS MetS p
Patients (%) 349 262/349 (75 %) 87/349 (25 %)
Age, years 64.5 ± 6.09 (66;61/69) 64.05 ± 6.53 (65;59/69) 64.92 ± 4.87 (65;62/68) 0.473
BMI, kg/m2 27.4 ± 12.77 (26.12;24/29) 26.56 ± 3.69 (26;24/28.4) 28.64 ± 3.45 (28;26.3/30.57) <0.001
PSA, ng/ml 9.87 ± 11.84 (7.07;5.08/10) 10.41 ± 12.28 (7.11;5.1/9.8) 10.80 ± 16.75 (8.18;4.39/11.95) 0.687
TRUS Volume, ml 53.07 ± 29.59 (48;35.1/60) 55.43 ± 34 (47.75;36/60) 53.4 ± 24.01 (50;37/67) 0.661
Waist, cm 99.51 ± 9.85 (99;94/106) 98.87 ± 9.45 (98;93/105) 102.77 ± 11.3 (102.5;96/110) 0.009
Glycemia, mg/dl 101.86 ± 23.42 (96;88/108) 98.48 ± 19.15 (94;87/104) 113.19 ± 25.7 (111;97/111) 0.003
Triglyceridemia, mg/dl 131.8 ± 64.4 (115;83.7/161.2) 126.07 ± 58 (110;83/155) 152.11 ± 78.88 (133;87/199.5) 0.040
HDL, mmol/l 51.8 ± 14.06 (50;42/59) 52.87 ± 13.44 (51;43/60) 47.72 ± 15.9 (45;36.5/57) 0.023
Hypertension 182/349 (52 %) 113/262 (43 %) 69/87 (79 %) <0.001
Data are presented as mean ± SD (median; IQR)
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Table 2 Patient’s Characteristics according to pathological Stage and Gleason score
< pT3a ≥ pT3a p GS < 4 + 3 GS≥ 4 + 3 p
Patients (%) 223 (64 %) 126 (36 %) 204 (58.5 %) 145 (41.5 %)
Age, years 63.44 ± 6.28 (65;59/68) 65.97 ± 5.97 (66;62/70) <0.001 63.43 ± 6.16 (64;59/68) 64.69 ± 6.28 (66;61/69) 0.158
TRUS Volume, ml 76 ± 44.05 (60;44/96) 51.53 ± 29.86 (47;33.6/60) <0.001 56.31 ± 31.57 (50;38/62.5) 53.23 ± 29.54 (49.5;35.5/57.9) 0.018
Waist, cm 99.30 ± 8.13 (98.87;96/102.77) 100.34 ± 9.22 (98.87;96/102.77) 0.503 99.21 ± 8.88 (99;94/105) 98.63 ± 10.89 (97;92/103) 0.549
BMI, kg/m2 26.64 ± 3.59 (26.98;24/28.65) 27.07 ± 3.79 (26.4;24/30) 0.149 26.51 ± 3.54 (26.98;24/28.4) 27.10 ± 3.8 (26.52;24/29.2) 0.131
PSA, ng/ml 7.81 ± 4.55 (6.8;4.79/9.43) 14.54 ± 17.84 (8.28;6.23/14.09) <0.001 8.79 ± 8.16 (6.6;4.96/9.42) 13.22 ± 18.22 (8.7;6.15/11.7) <0.001
Trygliceridemia, mg/dl 130.65 ± 63.4 (105;83/163) 136.23 ± 65.86 (122;86/161.5) 0.648 130.92 ± 50.74 (126;94/152) 135.25 ± 60 (126;94/152) 0.552
Glycaemia, mg/dl 100.83 ± 19.68 (98;91/104) 103.87 ± 21.1 (98;92/111) 0.159 100.19 ± 20.85 (95;88/107) 103.84 ± 23.15 (96;88/108) 0.153
HDL, mg/dl 52.14 ± 11.73 (52;45/56) 50.78 ± 12.34 (52;44/55.25) 0.925 52.1 ± 11.14 (52;46/55) 51.03 ± 12.99 (52;43/56.75) 0.213
Hypertension 102/223 (47 %) 74/126 (59 %) 0.037 88/204 (43 %) 91/145 (63 %) 0.001














Table 3 Univariable and multivariable analysis for predicting advanced pathological stage and high pathological grade PCa
Advanced pathological stage (≥ pT3a or N1) High pathological Gleason Score (≥4 + 3)
Crude OR p Multivariable p Crude OR p Multivariable p
Age, years OR: 1.051 (CI: 1.010-1.094) 0.014 OR: 1.044 (CI: 0.997-1.094) 0.006 OR: 1.021 (CI: 0.984-1.060) 0.268 OR: 1.001 (CI: 0.961-1.044) 0.949
TRUS Volume, ml OR: 0.994 (CI: 0.987-1.002) 0.155 OR: 0.993 (CI: 0.983-1.003) 0.173 OR: 0.997 (CI: 0.989-1.004) 0.356 OR: 0.998 (CI: 0.989-1.006) 0.594
PSA, ng/ml OR: 1.068 (CI: 1.033-1.134) 0.001 OR: 1.121 (CI: 1.060-1.185) 0.001 OR: 1.038 (CI: 1.012-1.065) 0.004 OR: 1.064 (CI: 1.024-1.106) 0.002
BMI, kg/m2 OR: 1.016 (CI: 0.945-1.092) 0.673 OR: 1.027 (CI: 0.957-1.102) 0.459
MetS OR: 2.439 (CI: 1.492-3.987) 0.004 OR: 2.697 (CI: 1.481-4.913) 0.001 OR: 1.886 (CI: 1.164-3.054) 0.010 OR: 1.880 (CI: 1.066-3.316) 0.029
Waist, cm OR: 1.016 (CI: 0.990-1.043) 0.218 OR: 1.009 (CI: 0.984-1.034) 0.494
Glycaemia, mg/dl OR: 1.007 (CI: 0.996-1.018) 0.203 OR: 1.007 (CI: 0.997-1.018) 0.181
Trygliceridemia, mg/dl OR: 1.001 (CI: 0.997-1.005) 0.565 OR: 1.002 (CI: 0.998-1.005) 0.423
HDL, mg/dl OR: 1.001 (CI: 0.983-1.019) 0.947 OR: 0.992 (CI: 0.974-1.010) 0.374
Hypertension OR: 1.621 (CI: 0.987-2.662) 0.056 OR: 2.180 (CI: 1.330-3.575) 0.002














prostate volume and PCa extent and aggressiveness
[1, 25–29]. Specifically, Freedland et al reported a signifi-
cantly higher incidence of advanced disease in men with
small prostates [25]; Kassouf et al described that more
poorly differentiated tumors were found at RP in subjects
with small prostate volumes than in those with larger
glands [28]. The biological mechanism accountable for the
inverse association between prostate volume and cancer
aggressiveness remains to be explicated. Since more PSA
diffuses into the circulation from cancerous cells than
from benign prostatic tissues, it is theorized that men with
higher PSA density may have an increased risk of harbour-
ing high-grade/advanced-stage PCa [30].
In the present study we observed that MetS is a com-
mon condition (87/349, 25 %) among patients undergo-
ing RP and is more prevalent than obesity (56/349,
16 %). In a previous experience, we reported that MetS
was even more prevalent (44 %) in patients at risk of
PCa for an elevated PSA or an abnormal digital rectal
examination and we also showed that MetS was associ-
ated with an increased risk (OR: 3.8; 95 % CI 1.33-10.9)
of Gleason score ≥ 7 in patients with PCa at biopsy [1].
Our results have been later confirmed by Morote et al
[14] (OR 1.75; 95 % CI 1.26-2.41) and Kayaly et al [12]
(OR 1.8; 95 % CI 0.87-3.74) on similar bioptic studies.
Notwithstanding all these studies, the association
between MetS and PCa is still controversial. Most of the
studies conducted on the European population have
demonstrated a positive association between MetS and
PCa incidence, aggressiveness and outcomes [9, 11, 13].
Similar cohort studies performed on Americans revealed
null [17] or inverse [16] associations. Making a compari-
son between our series and the USA one may be
misleading because of heterogeneity in age, race and
BMI distribution. Our cohort is entirely Caucasian with
neither Africans nor Hispanics and, although in line with
the average Italian population, it is less obese (16 % vs
34 %) and older (median age 66 vs 62 years) when com-
pared to other experience from USA series [1, 6, 31]. In
2013, Xiang et al conducted a meta-analysis confirming
a weak association between MetS and PCa risk, although
men with MetS appeared more likely to have a grater
risk of biochemical progression after RP and a higher
cancer-specific mortality [18]. Bhindi and colleagues
recently highlighted that no individual MetS component
is independently associated with PCa outcomes, however
a correlation between the number of MetS components
and the odds of PCa diagnosis exists, with a biologic gra-
dient present [10]. Finally, data from a recent study
based on the REDUCE (Reduction by Dutasteride of
Prostate Cancer Events) population confirmed that hav-
ing two or three to four MetS features was associated
with increased risk of high-grade PCa (OR 1.35 and 1.94
respectively) [15].
One of the most important limitations and criticisms
of the available evidence on the relationship between
PCa and MetS is the lack of confirmatory studies on RP
as most of the studies were performed on prostate bi-
opsy cohorts where a significant percentage of patients
with a negative biopsy unfortunately harbour a PCa. In
order to overcome these limitations, we designed the
first prospective multicentre study conducted on a
consecutive series of patients undergoing RP using a
standardized definition of MetS as the one proposed by
ATPIII [5]. We observed that MetS is significantly asso-
ciated with advanced PCa: patients with MetS presented
a 2-fold increased risk of advanced stage and high-grade
cancer. Our results are also supported by the retrospective
single centre study presented by Kheterpal E et al [32], al-
though data are not comparable since the author defined
the presence of MetS using the criteria proposed by the
International Diabetes Federation.
The biological mechanisms explaining these findings
remain unknown. MetS features are known to accompany
a pro-inflammatory state (elevated levels of C-reactive
protein, TNF-α, interleukin 8, 6, 1β), which in turn has
been related to prostate cancer risk [33–36]. Moreover,
men with MetS are commonly diagnosed with hyperinsu-
linemia that has been associated with increased risk of
PCa death. Finally, elevated circulating levels of IGF-1,
leptin and adiponectin, commonly encountered in MetS
patients, have all been associated with prostate cancer risk.
However, current knowledge probably represents a
minimal part of the biological mechanisms behind these
associations and forthcoming studies are awaited [6].
We must acknowledge some limitations of our study.
This is a multicentre study of patients with prostate
cancer undergoing radical retropubic prostatectomy with
a limited population of Caucasian men with no Africans
or Hispanics; so far, our results cannot be extended to
all patients with prostate cancer. Furthermore, a
comprehensive evaluation of the association between
MetS and PCa should include data on the different
therapeutic options available for the management of T1-
T3 PCa patients. However, although a trial investigating
the impact of MetS in patients treated with External
Beam Radio Therapy is ongoing in one of our centres
and data will be soon available, the current study did not
evaluate other possible treatment options. Considering
the conflicting results reported by different authors
when investigating the association between MetS and
PCa in non-European populations, confirmatory findings
from multicentre studies based on larger cohorts of
patients of different ethnicities, receiving different
treatment, are warranted.
Another limitation derives from the lack of informa-
tion in the current study regarding physical activity or
diet, which are associated with MetS, risk of PCa and
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potentially cancer grade at diagnosis [6]. Finally the lack
of long-term oncologic outcomes, including at least
biochemical recurrence free and metastasis free survivals
does not allow supporting MetS as an independent
predictor of poor oncologic outcomes. However this
study is ongoing and results will be available in the near
future.
Notwithstanding all these limitations, our study is the
first prospective study evaluating patients treated with
RP using the ATPIII criteria to define the presence of
MetS. Our results, if confirmed, could open new issues
in the management of patients with PCa and MetS as
well as new studies investigating the role of physical
activity, diet and medical treatment for MetS on PCa
development and progression.
Conclusions
In our multi centre study, we firstly observed that MetS
is associated with an increased risk of high-grade
pathological Gleason score and advanced pathological
stage in patients with PCa treated with RP. Even though
the molecular pathways are yet to be understood, it is
assumable that metabolic factors should be considered as
possible drivers of PCa differentiation and progression.
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